An interventional study of low intensity focused ultrasound (LIFU) in Tobacco Use Disorder, sponsored by Washington D.C. Veterans Affairs Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-20.
Sponsored by Washington D.C. Veterans Affairs Medical Center · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 799 studies in Tobacco Use Disorder with a site in United States — 75 open to participants now, 91 under way, 5 of them phase 3. Tobacco Use Disorder · United States.
Among the 799 studies in Tobacco Use Disorder with a site in United States, this one is the 507th largest by planned enrollment of the 736 interventional ones that give a count, is one of 24 that started in 2022, is one of 364 with no phase, reaches primary completion later than 4 of the 90 other live ones, and was the 725th registered.
1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.
Browse Tobacco Use Disorder studies →75 of the 799 studies in Tobacco Use Disorder with a site in United States are open now. Recruiting first, the newest first:
Florida International University · Sites in United States
Ages 14–18
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 21+ · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 21+
VA Office of Research and Development · Sites in United States
Yale University · Sites in United States
Ages 21–44 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
799 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 110 · Phase 2 176 · Phase 3 66 · Phase 4 71
First in 1990; this study’s year is marked. 24 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 44 is below the median of 90 across 893 interventional studies indexed under Tobacco Use Disorder.
Median enrollment 84 across the 736 interventional studies, 112 across the 58 observational. Of the 656 that completed or were terminated, 344 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 799 have an industry lead sponsor. The 10 most frequent:
Washington D.C. Veterans Affairs Medical Center is the lead sponsor of 19 studies on the registry; 6 are open to participants now.
Washington D.C. Veterans Affairs Medical Center has 1 study filed under Tobacco Use Disorder — fewer than ten, so there is no comparison to draw.
41 of the studies in Tobacco Use Disorder with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04176172Phase 3Abramson Cancer Center at Penn MedicineOptimizing Tobacco Use Treatment for PLWHA | 2026-11-30 |
| NCT06837220University of ChicagoImplementation of Tobacco Cessation Programming at Community Behavioral Health Sites | 2026-12 |
| NCT05452772Johns Hopkins University5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder | 2026-12 |
| NCT07322432VapeAwayThe CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction | 2026-12 |
| NCT06617312University of California, Los AngelesExamining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity | 2026-12 |
Add all 41 to your calendar (.ics) → With an account.
Among the 799 studies in Tobacco Use Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to to inhibit the dorsal anterior insula (dAI) with low intensity focused ultrasound (LIFU) to determine the causal role for the dAI in smoking cue induced craving in individuals with tobacco use disorder (TUD); smoking cue induced craving is a clinically important behavior which has been associated with the severity of nicotine addiction. The main question[s] it aims to answer are:
Participants will undergo anatomical MRI, neurological assessment, clinical assessment and patient query to assess the safety and tolerability of LIFU vs sham.
Participants will undergo functional magnetic resonance imaging where we will measure the effect of LIFU vs sham on 1) dAI blood-oxygen-level-dependent (BOLD) activation in response to smoking (compared to neutral) cue exposure and 2) cue-induced craving in individuals with TUD. Each participant will receive LIFU and sham stimulation.
Tobacco use disorder (TUD) remains the leading cause of preventable death in the world. Costs of smoking related illness in the United States totals more than $300 billion each year. The majority of adult cigarette smokers want to quit and more than half make an attempt but fewer than 1 in 10 smokers successfully quit at the end of 1 year. Rates of cigarette smoking are higher and cessation rates are lower in the veteran population in the United States compared to the nonveteran population. Noninvasive neuromodulation holds promise as a therapeutic approach to TUD as evidenced by the recent food and drug administration (FDA) clearance of deep transcranial magnetic stimulation (TMS) as such a treatment. One additional, emerging potential therapeutic is using low-intensity focused ultrasound (LIFU) to inhibit cortical and deep brain regions. The enormous potential of LIFU stems from the ability to focus ultrasound through the intact skull to a millimeter-sized focal spot size anywhere in the brain. This makes it a powerful alternative to both invasive neurosurgical procedures and other noninvasive brain stimulation techniques such as TMS that have limited spatial resolution and can only reach superficial areas of the brain. One promising target to treat TUD is the dorsal anterior insular cortex (dAI), a brain structure whose function is linked to the desire to smoke. The dAI is a part of the salience network (SN) that is involved in assigning significance and emotional value to stimuli and is consistently activated with exposure to smoking cues and craving. Remarkably, humans with damage to the insula were able to stop smoking easily and without experiencing cravings or relapse. As such, the insula is a promising target for reducing craving and use in individuals with TUD. Unfortunately, the dAI is small and lies deep within the lateral sulcus covered by the overlying opercula of the temporal lobe and is not accessible with conventional noninvasive neuromodulatory techniques. LIFU can selectively target the dAI and provides a potentially transformative method to reduce nicotine craving and addiction. The overall purpose of this proposal is to inhibit the dAI with LIFU to determine the causal role for the dAI in smoking cue induced craving which is a clinically important behavior which has been associated with the severity of nicotine addiction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
double-blind, sham-controlled, crossover study in N=44 individuals with Tobacco Use Disorder
Device: low intensity focused ultrasound (LIFU)
double-blind, sham-controlled, crossover study in N=44 individuals with Tobacco Use Disorder
Device: low intensity focused ultrasound (LIFU)
Low-intensity focused ultrasound (LIFU) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. LIFU is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth. Much lower intensities of focused ultrasound (LIFU) are used so that tissue damage does not occur, but neural activity can be modulated. LIFU utilizes acoustic energy at much lower levels to affect tissue by mechanical effects.
Incidence of Treatment-Emergent Adverse Events
number of adverse events
Time frame: immediately prior to 1 session LIFU and within 1 hour post LIFU; immediately prior to 1 session sham and with in 1 hour post shamdays
Smoking cue-induced craving
numerical craving rating scale Score Range: 0-100 (Higher score meaning worse outcome) 0 = No thoughts of Craving 100 = All of your thoughts of craving
Time frame: immediately prior to 1 session LIFU and within 1 hour post LIFU; immediately prior to 1 session sham and with in 1 hour post sham
Plan to share: Yes — behavioral and imaging data
Supporting information: Statistical analysis plan, Analytic code
Time frame: data will be available after analysis of primary and secondary outcomes are completed
No publications or documents are linked to this record.
Started Apr 2022 (actual). Primary completion is estimated for Mar 2026, 47 months after the start.
Of 257 non-industry interventional studies with no phase under Tobacco Use Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's planned 47 months is above that.
Counting every sponsor, half of 267 studies reached it within 32 months; a quarter within 16 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Washington D.C. Veterans Affairs Medical Center